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Acetylation is the major route of metabolism of many 
drugs including the antiarrhythmic agent procainamide. 
Coadministration of para-aminobenzoic acid was ob•
served to decrease the biotransformation of procain•
amide to N-acetylprocainamide in a patient with rapid 
acetylation kinetics. In view of the distinct antiar-
Biotransfonnation of phannacologic agents may result in 
either the inactivation or the synthesis of metabolites that 
have undesirable metabolic or toxic effects. In theory, the 
administration of compounds that inhibit biotransfonnation 
may be useful in diverse clinical situations. One such pos•
sibility is the modulation of the metabolism of procain•
amide, which is acetylated to N-acetylprocainamide (1). The 
involved enzyme arylamine N-acetyltransferase (EC 2.3.1.5) 
is located in several mammalian tissues and will acetylate 
numerous substrates (2). Various drugs inhibit the in vitro 
acetylation of procainamide (3); however, we know of no 
studies that demonstrate inhibition of acetylation in human 
subjects (4). 
The basis for our attempt was the observation that our 
patient experienced episodes of sustained ventricular tachy•
cardia while receiving long-tenn oral procainamide therapy. 
However, he responded to intravenous administration of 
high doses of the same agent. The finding of high serum 
concentrations of N-acetylprocainamide, together with rel•
atively low levels of procainamide during oral therapy, pro•
vided one possible explanation. N-acetylprocainamide has 
antiarrhythmic properties that differ from those of procain•
amide, and the combined electrophysiologic effects of pro•
cainamide and N-acetylprocainamide may not resemble those 
of procainamide alone (5,6). To limit the synthesis of N•
acetylprocainamide, we used para-aminobenzoic acid, which 
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rhythmic and toxic properties of procainamide and N•
acetylprocainamide, the observed drug interference may 
have great clinical relevance in long-term oral antiar•
rhythmic therapy and in instances where other drugs 
converge for acetylation. 
(J Am Coil CardioI1986;7:185-7) 
is a substrate for the acetylase and has been administered 
orally with limited toxicity. 
Case Report 
A 61 year old white man was admitted to this center 
after multiple episodes of sustained ventricular tachycardia 
that occurred despite therapy with sustained-release pro•
cainamide. With long-tenn oral therapy, serum levels were 
5.6 JLg/ml for procainamide and 19.0 JLg/ml for N-acetyl•
procainamide. Results of renal and liver function tests were 
nonnal (glomerular filtration rate 129 mllmin). 
Initial study and treatment. Electrophysiologic testing 
was perfonned 48 hours after procainamide withdrawal. 
Sustained ventricular tachycardia was reproducibly induced 
after two premature ventricular stimuli. Procainamide (1.5 
g) was intravenously infused and testing was repeated. We 
could not induce sustained ventricular tachycardia despite 
administration of three premature stimuli. Antiarrhythmic 
drug treatment was not resumed in anticipation of further 
drug testing. Multiple episodes of sustained ventricular 
tachycardia were recorded; these were tenninated by a bolus 
infusion of intravenous procainamide (1.5 g). A constant 
intravenous infusion of procainamide was then started (Fig. 
1). Because of the high serum N-acetylprocainamidei 
procainamide ratio. para-aminobenzoic acid was adminis•
tered (as the potassium salt). Soon after the administration 
of para-aminobenzoic acid. the N-acetylprocainamidel 
procainamide ratio reversed significantly and reversed 
again after withdrawal of the para-aminobenzoic acid. 
A rechallenge on a second date again reversed the 
ratio. No side effects were noted by the patient and 
no sustained episodes of ventricular tachycardia occurred 
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Figure 1. Serum level of procainamide 
(PA) and N-acetylprocainamide (NAPA) 
before, during and after the introduction 
of oral dose (P.O.) of potassium para•
aminobenzoic acid (POT ABA). The pa•
tient received continuous intravenous 
(I. V.) procainamide as indicated with an 
occasional bolus injection according to 
the level of monitored arrhythmia. The 
duration of observation is shown in hours 
on the abscissa. The procainamide and 
N-acetylprocainamide levels were mea•
sured by spectrophotometry (Dupont 
ACA III analyzer). 
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while the patient received the procainamide infusion with 
para-aminobenzoic acid. 
Because of episodes of nonsustained ventricular tachy•
cardia, the patient was discharged on flecainide acetate ther•
apy, which appeared to both eradicate spontaneous arrhyth•
mias and suppress ventricular tachycardia in the electro•
physiology laboratory. 
Readmission studies and treatment. The patient was 
readmitted 3 months later, again with sustained ventricular 
tachycardia. The tachycardia was again terminated by bolus 
infusion of procainamide (400 mg intravenously). Procain•
amide (sustained release, 750 mg orally every 6 hours) was 
added to the flecainide. Steady state levels of procainamide 
and N-acetylprocainamide were drawn after 48 hours of 
treatment (Table 1). Similarly, urine samples were obtained 
for determination of procainamide and N-acetylprocain•
amide levels. Ventricular extrasystoles were quantified at 
steady state. Para-aminobenzoic acid (1.5 g) was admin•
istered orally every 6 hours. After 30 hours of administra-
Table 1. Plasma Levels and Urinary Ratios of Procainamide 
(PA) and N-Acetylprocainamide (NAPA) and Hourly Premature 
Ventricular Complex (PVC) Averages 
Control 
With Para-aminobenzoic 
Acid 
Time* PA NAPA NAPNPA PA NAPA NAPNPA 
2 3.48 8.25 2.37 5.49 6.59 1.20 
4 3.00 8.71 2.90 5.04 6.62 1.31 
6 2.96 8.31 2.81 4.86 6.64 1.37 
PVCs/h 32 PVCs/h 7 
Urinary NAPNPA 2.33 Urinary NAPNPA 0.85 
*Time is given in hours after dose. Procainamide and N-acety1pro•
cainamide levels are in milligrams per liter. 
tion, steady state levels of procainamide and N-acetylpro•
cainamide were measured and arrhythmic evaluation was 
again performed (Table 1). The patient had marked suppres•
sion of extrasystoles and no sustained arrhythmias with re•
versal of the serum N-acetylprocainamide/procainamide ra•
tio. Of note is that this ratio in the urine decreased, consistent 
with either decreased N-acetylprocainamide excretion or, 
more likely, increased procainamide excretion. He was then 
discharged from the hospital receiving flecainide, procain•
amide and para-aminobenzoic acid. 
Discussion 
There have been limited in vivo studies of inhibition of 
acetylation, especially with respect to procainamide. The 
acetylation may be under the control of the hepatic acetylase 
which has bimodal distribution in humans (1). Other studies 
(7), however, suggest that procainamide acetylation is reg•
ulated by a unimodally distributed enzyme (which acetylates 
para-aminobenzoic acid, para-aminosalicylic acid and 
sulfanilamide) . 
Because procainamide and N-acetylprocainamide have 
different antiarrhythmic effects (the latter having its major 
effect by prolonging action potential duration (5), but ad•
ditive toxicities, it may be advantageous in certain patients 
to be able to manipulate the N-acetylprocainamidel 
procainamide ratio. Our patient appeared to have a clear 
acute clinical response to procainamide. However, he did 
not respond to oral procainamide therapy, during which the 
level of serum N-acetylprocainamide was relatively high in 
relation to procainamide. The administration of para-ami•
nobenzoic acid, a potential competitive inhibitor of the ace•
tylation of procainamide, resulted in a reproducible decrease 
in the N-acetylprocainamide/procainamide ratio. Because 
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lis urinary N-acetylprocainamide/procainamide ratio de•
:reased with para-aminobenzoic acid, it is unlikely that the 
lara-aminobenzoic acid decreased renal excretion of 
lrocainamide. 
At the present time, there are suggestive in vitro data on 
:ompetitive inhibition of acetylation by coadministration of 
frugs including procainamide (3). Information is also avail•
lble in human subjects, for example, the toxic effects of 
soniazid are decreased with the coadministration of para•
lminosalicylic acid and streptomycin (8). Further studies to 
:larify interactions between drugs that use the same enzyme 
iystems for degradation may be of great clinical utility in 
lltering the biotransformation of drugs by this technique. 
IV e appreciate the technical assistance of M. Hennckson 
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